Shanghai Junshi Biosciences (8SJ) Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
8SJ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Shanghai Junshi Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.12 |
| 52 Week High | HK$4.06 |
| 52 Week Low | HK$1.71 |
| Beta | 0.56 |
| 1 Month Change | 19.10% |
| 3 Month Change | -23.19% |
| 1 Year Change | -17.83% |
| 3 Year Change | -26.39% |
| 5 Year Change | n/a |
| Change since IPO | -60.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8SJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.2% | -1.1% | -0.5% |
| 1Y | -17.8% | 13.3% | 0.3% |
Return vs Industry: 8SJ underperformed the German Biotechs industry which returned 13.3% over the past year.
Return vs Market: 8SJ underperformed the German Market which returned 0.3% over the past year.
Price Volatility
| 8SJ volatility | |
|---|---|
| 8SJ Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 8SJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8SJ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2,903 | Cong Li | www.junshipharma.com |
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis.
Shanghai Junshi Biosciences Co., Ltd. Fundamentals Summary
| 8SJ fundamental statistics | |
|---|---|
| Market cap | €4.26b |
| Earnings (TTM) | -€85.51m |
| Revenue (TTM) | €352.48m |
Is 8SJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8SJ income statement (TTM) | |
|---|---|
| Revenue | CN¥2.72b |
| Cost of Revenue | CN¥584.05m |
| Gross Profit | CN¥2.14b |
| Other Expenses | CN¥2.80b |
| Earnings | -CN¥660.86m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 27, 2026
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 78.56% |
| Net Profit Margin | -24.26% |
| Debt/Equity Ratio | 97.3% |
How did 8SJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/22 00:00 |
| End of Day Share Price | 2026/07/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Junshi Biosciences Co., Ltd. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Congmin Yuan | Citic Securities Co., Ltd. |
| Muk Tsz Yung | Citigroup Inc |